Multiple Myeloma Progression
12
4
5
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
8.3%
1 terminated out of 12 trials
0.0%
-86.5% vs benchmark
0%
0 trials in Phase 3/4
0%
1 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (12)
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
Tinostamustine Conditioning and Autologous Stem Cell
CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM